Finally Some real rational thought on the board! NP announces an investor call but how has that changed the fundamentals of whether or not LL gets approval? GILD got approval in 2 days but they had like 5000 people taking it all over the world with hundreds of recruiting sites. Putting things into perspective we have 87 patients worth of data for the FDA to consider and its phenomenal but its only 87 in this indication. When they get the SC data the chances of approval should go into the high 90's because it was labeled a pivotal trial and mortality is the endpoint so if we crush 28 day all cause mortality we become the first drug in COVID-19 to actually meet its primary endpoint of a randomized double blind clinical trial.

Very bullish on the stock. The longs on the board saying here we go again all talk and no action are playing right into the hands of the shorts. Its constructive to debate what hes going to talk about but the focus should be on what sort of announcements might come out. For example - journal articles or initiation of more clinical trials.

the biggest wild card is media. anyone that breaks this story might catapult the price. What about major brokerage coverage? Maybe even an upgrade in price target.